Full-Time
Staff Embedded Engineer
Posted on 9/24/2025
Ceribell
201-500 employees
EEG headband device for brain monitoring
Compensation Overview
$175k - $200k/yr
Sunnyvale, CA, USA
In Person
Location derived from 'Locations: sunnyvale, ca'. No remote option mentioned in job description. Hybrid/in-person not specified; given single in-person location, treat as in-person.
 Software Engineering (1) |
|---|
- Bachelor’s Degree in electrical engineering, computer science, biomedical engineering or related field. Graduate degree preferred.
- 10+ years of experience in embedded software development of a commercial product. Medical device experience preferred.
- 3+ years of professional experience in embedded Linux software development, interfacing with peripherals, and configuring device drivers and associated toolchains, e.g. Ubuntu, Torizon, Yocto, Buildroot.
- Experience with bootloaders (U-Boot, security-boot), and system startup.
- Experience with GUI-based application development in e.g. Qt preferred.
- Experience using Git for version control.
- Proficient in C/C++.
- Direct experience with development of WiFi connected/IoT devices preferred.
- Strong analytical skills, detail-oriented and collaborative.
- Develop, test, and maintain software features for Ceribell’s EEG systems.
- Work with cross-compilation toolchains, build systems (Yocto, Buildroot, or similar), bootloaders, and CI/CD pipelines.
- Develop, integrate, and debug device drivers for various peripherals (I²C, SPI, UART, USB, PCIe, etc.).
- Troubleshoot and resolve complex issues across the software/hardware boundary.
- Understand user needs and translate them to the development of new and improved features.
- Participate in code reviews, peer reviews, and risk management activities.
- Provide input on firmware and hardware architecture for new and existing products.
- Experience in embedded or IoT products development
- Prior biomedical/medical device experience
- Experience with STMicroelectronics STM32 ARM Cortex microcontroller, FreeRTOS, IAR Embedded Workbench, and TouchGFX framework is in description so not to be repeated as desirable?
Ceribell makes and sells medical devices that monitor brain activity in hospitals. Its main product is the Ceribell EEG Headband and Recorder, worn by patients and used by trained healthcare providers in clinical settings to collect EEG data. The device captures brain signals and stores them for clinicians to review; it does not diagnose conditions or send automated alerts, leaving interpretation and treatment decisions to physicians. The system is designed for time-sensitive situations, such as Nonconvulsive Status Epilepticus (NCSE), where rapid data can help guide urgent care. Revenue comes from selling the devices to healthcare facilities, with purchases made on physician orders as required by US law. Compared with competitors, Ceribell emphasizes fast, clinician-driven data collection for urgent neurological cases and does not replace clinical judgment with automated diagnoses or alerts.
Company Size
201-500
Company Stage
Series C
Total Funding
$171M
Headquarters
Mountain View, California
Founded
2014
Simplify's Take
What believers are saying
- Q1 2026 revenue hit $26.5M, up 29% YoY, with 87% gross margins and record headband utilization.
- FedRAMP High authorization unlocks sales to 170-hospital VA system.
- FDA Breakthrough Designation for LVO stroke detection accelerates review for new $3.5B TAM.
What critics are saying
- Post-IPO lock-up expiry on April 9 depresses CBLL stock via insider selling.
- Natus Medical's BrainZ BR8 undercuts with 50% lower disposables in 500+ hospitals.
- CMS rejects NTAP for delirium due to insufficient trial data, delaying reimbursement.
What makes Ceribell unique
- Ceribell offers world's first FDA-cleared continuous AI-powered delirium monitoring via EEG headband.
- Clarity algorithm provides FDA-cleared seizure detection from preterm newborns to adults.
- Instant EEG headcap deploys in 6 minutes without EEG technologist, enabling bedside use.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Unlimited Paid Time Off
Paid Holidays
Parental Leave
Annual Bonus Opportunity
Company Equity
Phone/Internet Stipend
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 1%CeriBell Conference: CFO highlights 36% revenue growth, expands EEG platform to pediatrics and delirium. MarketBeat In this article: Key points. * $89 million revenue in 2025 with 36% YoY growth and 88% gross margins, plus $159 million cash and 31 consecutive quarters of sequential growth - yet only ~3% penetration (647 of ~6,000 U.S. hospitals), signaling substantial upside. * CeriBell expanded its platform with pediatric/neonatal algorithm clearance and an infant head cap (launch planned in Q2), received FDA clearance for delirium in Nov 2025 and raised its TAM to about $3.5 billion, and secured an FDA breakthrough designation for stroke in Jan 2026. * The commercial model combines ~25% subscription revenue (≈97% gross margin) and ~75% disposable headbands, while go-to-market investments expanded territory coverage from ~35 to 55 and achieved FedRAMP clearance to enable VA sales. * Interested in CeriBell, Inc.? Here are five stocks Penneco Pipeline Corp. like better. CeriBell (NASDAQ:CBLL) is seeking to accelerate adoption of its point-of-care EEG platform in U.S. hospitals while expanding into new patient populations and indications, Chief Financial Officer Scott Blumberg said at the 47th Annual Raymond James Institutional Investors Conference. Blumberg told investors the company ended 2025 with $89 million in revenue, representing 36% year-over-year growth, and delivered 88% gross margins for the year. CeriBell's commercial focus has been seizure detection in acute care settings such as the ICU and emergency department, which Blumberg described as an approximately $2 billion total addressable market. He added that the company reached multiple milestones during 2025 aimed at expanding its opportunity, including algorithm expansion to neonatal and pediatric patients and a first clearance related to delirium detection, which he said increased CeriBell's total addressable market to about $3.5 billion. Product focus: rapid EEG and bedside seizure detection. Blumberg positioned CeriBell's technology as addressing a critical challenge in diagnosing non-convulsive seizures in acute care. In contrast to epilepsy-related seizures that are often visible, seizures in ICU and ED settings are frequently non-convulsive, can persist for hours or days, and can be life-threatening. He said 92% of seizures in these patients are non-convulsive, making EEG the only way to diagnose them. He emphasized the importance of time-to-diagnosis in cases of prolonged seizure activity, including "status epilepticus," which he described as a society-defined term for a seizure lasting five minutes or more. Delays can worsen outcomes, and he noted that first-line treatment effectiveness declines as time passes, citing a one-hour delay as materially reducing effectiveness.
CeriBell, a medical device company specialising in point-of-care EEG monitoring, reported 36% annual revenue growth in Q4 2025 and expanded its addressable market from $2 billion to $3.5 billion through regulatory clearances for neonatal seizure detection and delirium monitoring. The company issued 2026 revenue guidance of $111 million to $115 million, with gross margins expected to remain in the mid-80% range. CeriBell plans to launch neonatal and paediatric products commercially in Q2 2026 and initiate a delirium monitoring pilot targeting a $1 billion market where no FDA-cleared device currently exists. The company expanded its commercial infrastructure to 55 territories and secured FedRAMP High authorisation, enabling access to the 170-hospital VA system. CeriBell maintains its commitment to achieving cash flow breakeven with existing capital.
Ceribell wins FDA Breakthrough Device Designation for ai-powered LVO stroke detection System. The Sunnyvale, CA-based firm's EEG-based solution uses artificial intelligence algorithms to identify large vessel occlusion strokes in hospital patients. The Ceribell System is a portable EEG platform. Image courtesy of Ceribell Ceribell has won Breakthrough Device Designation for its large vessel occlusion stroke detection and monitoring solution. This LVO stroke detection monitor uses Ceribell's existing hardware and applies an AI-based algorithm to interpret EEG signals for early detection of LVO stroke. "Stroke is a devastating condition, but one where quick access to treatment can make a lifetime of a difference," said Jane Chao, PhD, co-founder and CEO of Ceribell. "At a time when minutes matter, patients with in-hospital stroke often experience hours of delay. Ceribell is proud that this FDA Breakthrough Device Designation recognizes the potential of the Ceribell System to provide accurate and timely detection of LVO stroke for this vulnerable patient population." The Sunnyvale, CA-based company said the designation builds on recent FDA 510(k) clearances for its next-generation Clarity algorithm to detect electrographic seizures in neonates and its delirium screening and monitoring solution. In a research note, Brandon Vasquez, an analyst with William Blair, wrote, "We expect that FDA approval for stroke is likely still a few years out, but given the FDA approval for delirium was in line to slightly ahead of expectations, we believe it could be on the earlier side of that time frame." Vasquez went on to write, "Shares are roughly flat on the news, and we continue to believe our thesis on the compelling 2026 to 2027 setup is playing out. We wait for more updates on how much management expects catalysts like the pediatric/neonate rollout and delirium indication to impact 2026 revenue numbers next week. We expect the former to contribute more meaningfully, given the latter will likely go through a pilot phase before a large-scale rollout." All eyes are on Ceribell because the company went public in 2024, when IPOs were a rarity in medtech. The firm, founded in 2014, successfully raised $180.3 million in its IPO - significantly exceeding its initial goal of $101 million. In a November research note, BTIG analyst Marie Thibault wrote about the company's position in the point-of-care EEG market. Thibault wrote, "Ceribell is the clear market leader and continues to be the dominant player in POC EEG systems." Omar Ford is a seasoned journalist specializing in medical technology, healthcare innovation, and the medical device and diagnostics industry. As the editor-in-chief of Medical Device + Diagnostics Industry (MD+DI), he has earned a reputation as a leading authority in the field, offering in-depth insights into the latest trends, regulatory changes, and technological advancements shaping the future of healthcare. Omar has been a featured speaker at MD&M and MEDevice events. Omar has written for several publications prior to MD+DI. He is a former contributor at Bioworld Medtech, an online publication owned by Clarivate. He was a general assignment reporter for the Beaufort Gazette and an education and county reporter for the Griffin Daily News. He is the 2001 winner of the Judson Chapman Award from the South Carolina Press Association and the 2003 McClatchy President's Award recipient. Omar has a bachelor's degree in print journalism from the University of South Carolina. Throughout his tenure at MD+DI, Omar has covered a wide array of topics, including medical technology innovations, regulatory affairs, market dynamics, and the growing impact of artificial intelligence in healthcare. Omar is the host of the Let's Talk Medtech podcast.
SUNNYVALE, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) - CeriBell, Inc. (Nasdaq: CBLL) ("Ceribell" or the "Company"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced the appointment of Erica Rogers to its Board of Directors.
SUNNYVALE, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming William Blair 45th Annual Growth Stock Conference. The presentation will take place on Tuesday, June 3, 2025, at 7:20 a.m. Pacific Standard Time / 9:20 a.m. Central Standard Time.Event: William Blair 45th Annual Growth Stock ConferenceDate: Tuesday, June 3, 2025Time: 7:20 a.m. PST / 9:20 a.m